Efficacy News and Research

RSS

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

Potential new mRNA-based therapy for pre-eclampsia

Lipid nanoparticles targeting VEGF mRNA show promise in treating pre-eclampsia, restoring maternal blood pressure and enhancing fetal health in murine models.

13 Dec 2024

Lifestyle medicine education empowers clinicians

Clinicians who completed an American College of Lifestyle Medicine (ACLM) course introducing the foundations of lifestyle medicine and food as medicine reported significant improvements in their knowledge and confidence, as well as increases in how often they practice lifestyle medicine with patients, a research study found.

13 Dec 2024

Unraveling the mystery of drug-induced liver injury

DILI is broadly categorized into intrinsic and idiosyncratic types. Intrinsic hepatotoxins, such as APAP, cause dose-dependent injury, while idiosyncratic DILI involves complex immune and metabolic interactions that remain poorly understood.

13 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Mediterranean plants show promise for cardiovascular disease treatment

A study initiated from a final degree project at the Universitat Autònoma de Barcelona, with the involvement of researchers from the INc-UAB, the University of Barcelona and Cuban and Chilean institutions, has resulted in an exhaustive bibliographic review of a group of Mediterranean plants, whose active principles are attributed pharmacological actions in the field of cardiovascular diseases most affecting the population.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

electronRx to launch purpleDx pulmonary disease smartphone app for remote lung function monitoring

electronRx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it will launch purpleDx, a cardiopulmonary assessment app built to medical device standards, at CES 2025 from 7-10 Jan in Las Vegas, USA.

12 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and immunotherapy.

11 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic-;an effective antiviral that has since successfully treated millions.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status-;according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

1
2
3
4
...
1229
Next

Efficacy News and Research

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

Potential new mRNA-based therapy for pre-eclampsia

Lifestyle medicine education empowers clinicians

Unraveling the mystery of drug-induced liver injury

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Mediterranean plants show promise for cardiovascular disease treatment

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

electronRx to launch purpleDx pulmonary disease smartphone app for remote lung function monitoring

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

Exosomes: A double-edged sword in hepatocellular carcinoma

Understanding how angiogenesis contributes to drug resistance in breast cancer

New class of antivirals shows promise against multiple viruses

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Exploring the Future of Neuroscience Drug Discovery

Prostate cancer vaccines: Progress, challenges, and future directions

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Small solutions for big problems in drug discovery and delivery

Latest News